文献速递临床试验与 GCP流行病学与生物统计

创伤大输血风险患者早期使用四因子凝血酶原复合物的疗效与安全性:PROCOAG随机临床试验

Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

在法国12家一级创伤中心开展的双盲、随机、安慰剂对照优效性试验中,327例有大量输血风险的创伤患者随机接受4F-PCC或安慰剂,324例纳入分析。4F-PCC组24小时血液制品消耗量与安慰剂组无显著差异,但血栓栓塞事件更多,作者认为结果不支持系统性使用4F-PCC。

要点

  • 4F-PCC组24小时血液制品消耗中位数12U vs 安慰剂组11U,差异无统计学意义。
  • 4F-PCC组血栓栓塞事件56例(35%)vs 安慰剂组37例(24%),差异有统计学意义。
  • 作者认为结果不支持在有大量输血风险的创伤患者中系统性使用4F-PCC。

核心结论

  • 在有大量输血风险的创伤患者中,使用4F-PCC未显著减少24小时血液制品消耗,但血栓栓塞事件更常见,作者认为这些发现不支持系统性使用4F-PCC。

研究设计与样本

  • 双盲、随机、安慰剂对照优效性试验,2017年12月29日至2021年8月31日在法国12家一级创伤中心连续纳入有大量输血风险的创伤患者。
  • 干预为静脉给予4F-PCC 1 mL/kg(每公斤体重25 IU因子IX)vs 生理盐水1 mL/kg(安慰剂),患者、研究者和数据分析者均对治疗分配设盲。
  • 所有患者均接受早期比例输血(浓缩红细胞:新鲜冰冻血浆比例为1:1至2:1)并按欧洲创伤性出血指南治疗。
  • 4313例最高创伤级别启动患者中350例符合紧急纳入条件,327例随机分组,324例纳入分析(4F-PCC组164例,安慰剂组160例)。

主要发现

  • 参与者年龄中位数(IQR)为39(27-56)岁,损伤严重度评分为36(26-50,重大创伤),入院血乳酸为4.6(2.8-7.4)mmol/L。
  • 324例中179例(59%)院前动脉收缩压低于90 mm Hg,233例(73%)为男性,226例(69%)需要紧急止血控制。
  • 24小时血液制品消耗中位数(IQR)4F-PCC组为12(5-19)U vs 安慰剂组为11(6-19)U,绝对差异0.2 U(95%CI -2.99至3.33),P=0.72。
  • 4F-PCC组56例(35%)出现至少1次血栓栓塞事件 vs 安慰剂组37例(24%),绝对差异11%(95%CI 1%-21%),相对危险度1.48(95%CI 1.04-2.10),P=0.03。

临床怎么用

  • 作者认为这些发现不支持在有大量输血风险的创伤患者中系统性使用4F-PCC。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Optimal transfusion strategies in traumatic hemorrhage are unknown. Reports suggest a beneficial effect of 4-factor prothrombin complex concentrate (4F-PCC) on blood product consumption. OBJECTIVE: To investigate the efficacy and safety of 4F-PCC administration in patients at risk of massive transfusion. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, randomized, placebo-controlled superiority trial in 12 French designated level I trauma centers from December 29, 2017, to August 31, 2021, involving consecutive patients with trauma at risk of massive transfusion. Follow-up was completed on August 31, 2021. INTERVENTIONS: Intravenous administration of 1 mL/kg of 4F-PCC (25 IU of factor IX/kg) vs 1 mL/kg of saline solution (placebo). Patients, investigators, and data analysts were blinded to treatment assignment. All patients received early ratio-based transfusion (packed red blood cells:fresh frozen plasma ratio of 1:1 to 2:1) and were treated according to European traumatic hemorrhage guidelines. MAIN OUTCOMES AND MEASURES: The primary outcome was 24-hour all blood product consumption (efficacy); arterial or venous thromboembolic events were a secondary outcome (safety). RESULTS: Of 4313 patients with the highest trauma level activation, 350 were eligible for emergency inclusion, 327 were randomized, and 324 were analyzed (164 in the 4F-PCC group and 160 in the placebo group). The median (IQR) age of participants was 39 (27-56) years, Injury Severity Score was 36 (26-50 [major trauma]), and admission blood lactate level was 4.6 (2.8-7.4) mmol/L; prehospital arterial systolic blood pressure was less than 90 mm Hg in 179 of 324 patients (59%), 233 patients (73%) were men, and 226 (69%) required expedient hemorrhage control. There was no statistically or clinically significant between-group difference in median (IQR) total 24-hour blood product consumption (12 [5-19] U in the 4F-PCC group vs 11 [6-19] U in the placebo group; absolute difference, 0.2 U [95% CI, -2.99 to 3.33]; P = .72). In the 4F-PCC group, 56 patients (35%) presented with at least 1 thromboembolic event vs 37 patients (24%) in the placebo group (absolute difference, 11% [95% CI, 1%-21%]; relative risk, 1.48 [95% CI, 1.04-2.10]; P = .03). CONCLUSIONS AND RELEVANCE: Among patients with trauma at risk of massive transfusion, there was no significant reduction of 24-hour blood product consumption after administration of 4F-PCC, but thromboembolic events were more common. These findings do not support systematic use of 4F-PCC in patients at risk of massive transfusion. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03218722.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Bouzat P, Charbit J, Abback PS, et al. Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial. JAMA. 2023. PMID: 36942533. doi:10.1001/jama.2023.4080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。